glp 1 drugs and antidepressants Transformation 2.0: The GLP-1 RAs as Psychiatric Medications? The GLP-1 Agonists and Obesity:

Households with at least one GLP-1 user slashed their grocery spending by approximately 6% within six months of starting the medication as they pulled back on calorie-dense processed foods, according to a recent study by Cornell University and Numerator

Some researchers report improved exercise tolerance on retatrutide, possibly related to increased cardiac output

Unique MOAs & Combinations To achieve these unique outcomes, manufacturers are investigating novel mechanisms of action (MOAs) to target weight loss via multiple metabolic pathways

Rossing et al., 2023)

While several cardiovascular and renal outcome studies have been reported since publication of the 2018 ACC decision pathway, the document remains useful in terms of providing patient-specific considerations when determining which class of medications to select in a person with T2D